SK Biopharmaceuticals Co., Ltd. (KRX:326030)
 118,600
 +5,200 (4.59%)
  Last updated: Oct 31, 2025, 9:33 AM KST
SK Biopharmaceuticals Revenue
SK Biopharmaceuticals had revenue of 176.28B KRW in the quarter ending June 30, 2025, with 31.55% growth. This brings the company's revenue in the last twelve months to 620.28B, up 33.38% year-over-year. In the year 2024, SK Biopharmaceuticals had annual revenue of 547.60B with 54.30% growth.
Revenue (ttm) 
 620.28B
Revenue Growth 
 +33.38%
P/S Ratio 
 14.32
Revenue / Employee 
 2.52B
Employees 
 246
Market Cap 
8.88T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 547.60B | 192.70B | 54.30% | 
| Dec 31, 2023 | 354.89B | 108.71B | 44.16% | 
| Dec 31, 2022 | 246.18B | -172.47B | -41.20% | 
| Dec 31, 2021 | 418.64B | 392.65B | 1,510.23% | 
| Dec 31, 2020 | 26.00B | -97.85B | -79.01% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| Samsung Biologics | 5.03T | 
| Celltrion | 3.75T | 
| Yuhan | 2.17T | 
| Hanmi Pharm. | 1.47T | 
| PharmaResearch | 449.81B | 
| Sam Chun Dang Pharm. | 215.10B | 
| ALTEOGEN | 158.06B | 
| LigaChem Biosciences | 148.28B |